M-Xylene

M-Xylene

SCHEMBL1961587

Cc1cccc(C)c1.OBO

nearest known ligand 0.75

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ACHE P22303 5/20 0.75
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 1/20 0.50
PARP1 P09874 1/20 0.46
HTR3E A5X5Y0 1/20 0.44
HTR3B O95264 1/20 0.44
HTR3A P46098 1/20 0.44
HTR3D Q70Z44 1/20 0.44
HTR3C Q8WXA8 1/20 0.44
TP53 P04637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 2/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HSD17B10 Q99714 1/20 0.43
CYP1A2 P05177 2/20 0.42
NPC1 O15118 1/20 0.42
CASP3 P42574 1/20 0.42
SENP8 Q96LD8 1/20 0.42
SENP7 Q9BQF6 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
M-Xylene SCHEMBL11786968 0.87 ACHE (0.86) ACHEALDH1A1MAPK1PARP1HTR3E
M-Xylene SCHEMBL10427453 0.87 ACHE (0.86) ACHEALDH1A1MAPK1PARP1HTR3E
M-Xylene SCHEMBL6397624 0.87
M-Xylene SCHEMBL891494 0.87 ACHE (1.00) ACHEALDH1A1MAPK1PARP1HTR3E
M-Xylene SCHEMBL28189 0.87
M-Xylene SCHEMBL28161426 0.84 ACHE (0.80) ACHEALDH1A1MAPK1PARP1HTR3E
M-Xylene SCHEMBL5179379 0.83
M-Xylene SCHEMBL2292576 0.83 ACHE (0.92) ACHEALDH1A1MAPK1PARP1HTR3E
M-Xylene SCHEMBL358508 0.83
M-Xylene SCHEMBL4596533 0.83 ACHE (0.92) ACHEALDH1A1MAPK1PARP1HTR3E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11505545-B2 Anthelmintic quinoline-3-carboxamide derivatives BAYER ANIMAL HEALTH GMBH (DE) 2022-11-22 US disclosed
US-20220289751-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2022-09-15 US disclosed
EP-3999183-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF Ono Pharmaceutical Co., Ltd. (JP) 2022-05-25 EP disclosed
EP-3538512-B1 NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES BAYER ANIMAL HEALTH GMBH (DE) 2021-06-16 EP disclosed
US-20210115026-A1 NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES ELANCO ANIMAL HEALTH GMBH (DE) 2021-04-22 US disclosed
WO-2021010492-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2021-01-21 WO disclosed
US-10889573-B2 Anthelmintic quinoline-3-carboxamide derivatives BAYER ANIMAL HEALTH GMBH (DE) 2021-01-12 US disclosed
EP-3538512-A1 NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES Bayer Animal Health GmbH (DE) 2019-09-18 EP disclosed
CN-109021022-A Luminous diaza benzo imidazole carbene metal complex UDC 爱尔兰有限责任公司 2018-12-18 CN disclosed
CN-105431442-B Luminescent Diazabenzimidazole Carbene Metal Complexes UDC 爱尔兰有限责任公司 2018-08-07 CN disclosed
WO-2002070493-A1 BISARYL DERIVATIVES HAVING FSH RECEPTOR MODULATORY ACTIVITY PHARMACOPEIA, INC. (US) 2002-09-12 WO disclosed
WO-2002066478-A1 ANTAGONISTS OF GONADOTROPIN RELEASING HORMONE ASTRAZENECA AB (SE) 2002-08-29 WO disclosed
WO-2002066477-A2 IMIDAZOPYRIDINES ASTRAZENECA AB (SE) 2002-08-29 WO disclosed
US-6294580-B1 FOR THERAPY AND PROPHYLAXIS OF TYPE II OR NON-INSULIN DEPENDENT DIABETES MELLITUS, HYPERGLYCAEMIA, DYSLIPIDEMIA, TYPE II DIABETES, TYPE I DIABETES, HYPERTRIGLYCERIDEMIA, SYNDROME X, INSULIN RESISTANCE, HEART FAILURE GLAXO WELLCOME INC. 2001-09-25 US disclosed
EP-0888317-B1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LTD (GB) 2001-09-12 EP disclosed
EP-0888317-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1999-01-07 EP disclosed
WO-1997031907-A1 SUBSTITUTED 4-HYDROXY-PHENYLALCANOIC ACID DERIVATIVES WITH AGONIST ACTIVITY TO PPAR-GAMMA GLAXO GROUP LIMITED (GB) 1997-09-04 WO disclosed
EP-0199260-B1 BORONIC ACID ADDUCTS OF TECHNETIUM-99M DIOXIME COMPLEXES E.R. Squibb & Sons, Inc. (US) 1989-12-06 EP disclosed
US-4705849-A Boronic acid adducts of technetium-99m dioxime complexes E. R. SQUIBB & SONS, INC. (US) 1987-11-10 US disclosed
EP-0199260-A2 Boronic acid adducts of technetium-99M dioxime complexes E.R. Squibb & Sons, Inc. (US) 1986-10-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11505545-B2 Anthelmintic quinoline-3-carboxamide derivatives HRH4, HRH2, H1-5 ACHE 19/4885ALDH1A1 1655/4885MAPK1 4504/4885
US-20220289751-A1 COMPOUND HAVING KDM5 INHIBITORY ACTIVITY AND PHARMACEUTICAL USE THEREOF KDM5A, KDM1B, KDM5D ACHE 1082/4885ALDH1A1 2877/4885MAPK1 809/4885
US-20210115026-A1 NEW ANTHELMINTIC QUINOLINE-3-CARBOXAMIDE DERIVATIVES HRH4, HRH2, HRH1 ACHE 20/4885ALDH1A1 1833/4885MAPK1 4342/4885
US-10889573-B2 Anthelmintic quinoline-3-carboxamide derivatives HRH4, HRH2, H1-5 ACHE 20/4885ALDH1A1 1646/4885MAPK1 4518/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.